Meeting
2017 ASCO Annual Meeting
A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.
Authors
Linda R. Duska
University of Virginia Health System, Charlottesville, VA
Linda R. Duska , Timothy Norman Showalter , Gina R. Petroni , Timothy Bullock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT02635360
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5601)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5601
Abstract #
TPS5601
Poster Bd #
422b
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
A phase II study of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-ESO14-012 study.
First Author: Hirva Mansurali Mamdani
Poster
2016 ASCO Annual Meeting
Phase IB study of pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
First Author: Steven Francis Powell
Poster
2023 ASCO Annual Meeting
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
First Author: Jing Chen
Poster
2022 ASCO Annual Meeting
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.
First Author: Manuel Rodrigues